miR-486 targets Pim-1 kinase in lung cancer [26], OLFM4 in gastric cancer [20], CLDN10 and CITRON in hepatocellular carcinoma [24], and plasminogen activator inhibitor-1 in human myxoid liposarcoma [27]. This evidence concerns the gene SERPINE1 and gastric cancer.